Attached files
| file | filename |
|---|---|
| EX-32.1 - EXHIBIT 32.1 - REPROS THERAPEUTICS INC. | v465639_ex32-1.htm |
| EX-31.2 - EXHIBIT 31.2 - REPROS THERAPEUTICS INC. | v465639_ex31-2.htm |
| EX-31.1 - EXHIBIT 31.1 - REPROS THERAPEUTICS INC. | v465639_ex31-1.htm |
| 10-Q - FORM 10-Q - REPROS THERAPEUTICS INC. | v465639_10q.htm |
EXHIBIT 32.2
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Quarterly Report of Repros Therapeutics Inc. (the "Company") on Form 10-Q for the quarter ended March 31, 2017 as filed with the Securities and Exchange Commission on the date hereof (the "Report"), I, Katherine A. Anderson, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to my knowledge:
1. The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
| Dated: May 9, 2017 | By: | /s/ Katherine A. Anderson |
| Katherine A. Anderson | ||
| Chief Financial Officer | ||
| Repros Therapeutics Inc. | ||
| (Principal Financial Officer) |
A signed original of this written statement required by Section 906 has been provided to Repros and will be retained by Repros and furnished to the Securities and Exchange Commission or its staff upon request.